NCT05218902View on ClinicalTrials.gov

A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

CompletedOBSERVATIONAL
Enrollment

290

Participants

Timeline

Start Date

February 25, 2022

Primary Completion Date

March 20, 2023

Study Completion Date

March 20, 2023

Conditions
Myelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Trial Locations (1)

300010

Local Institution - 0001, Tianjin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05218902 - A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter